Q3 EPS Forecast for LENZ Therapeutics Boosted by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for LENZ Therapeutics in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.80) for the quarter, up from their prior forecast of ($0.87). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($0.45) EPS.

A number of other analysts have also recently issued reports on the company. Citigroup raised their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. TD Cowen began coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, May 8th. Finally, Piper Sandler started coverage on LENZ Therapeutics in a research note on Monday, April 14th. They issued an “overweight” rating and a $51.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.60.

LENZ Therapeutics Stock Up 11.5%

LENZ opened at $29.37 on Monday. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93. The stock has a market cap of $826.65 million, a price-to-earnings ratio of -16.59 and a beta of 0.41. The business has a 50 day moving average of $24.69 and a 200-day moving average of $27.32.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02.

Institutional Trading of LENZ Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in LENZ Therapeutics in the 4th quarter worth about $29,000. SG Americas Securities LLC raised its stake in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock worth $158,000 after purchasing an additional 935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LENZ Therapeutics by 14.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company’s stock worth $229,000 after purchasing an additional 1,005 shares in the last quarter. Rhumbline Advisers raised its stake in LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock worth $541,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after purchasing an additional 1,151 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.